Base de dados : MEDLINE
Pesquisa : E01.370.225.812 [Categoria DeCS]
Referências encontradas : 3415 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 342 ir para página                         

  1 / 3415 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28953993
[Au] Autor:Souza C; Zanchin NI; Krieger MA; Ludwig A
[Ad] Endereço:Fundação Oswaldo Cruz-Fiocruz, Instituto Carlos Chagas, Laboratório de Genômica Funcional, Curitiba, PR, Brasil.
[Ti] Título:In silico analysis of amino acid variation in human respiratory syncytial virus: insights into immunodiagnostics.
[So] Source:Mem Inst Oswaldo Cruz;112(10):655-663, 2017 Oct.
[Is] ISSN:1678-8060
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The highly contagious nature of human respiratory syncytial virus (HRSV) and the gravity of its infection in newborns and vulnerable adults pose a serious public health problem. Thus, a rapid and sensitive diagnostic test for viral detection that can be implemented upon the first appearance of symptoms is needed. The genetic variation of the virus must be considered for immunodiagnostic purposes. OBJECTIVES: To analyse HRSV genetic variation and discuss the possible consequences for capture immunoassay development. METHODS: We performed a wide analysis of N, F and G protein variation based on the HRSV sequences currently available in the GenBank database. We also evaluated their similarity with homologous proteins from other viruses. FINDINGS: The mean amino acid divergences for the N, F, and G proteins between HRSV-A and HRSV-B were determined to be approximately 4%, 10% and 47%, respectively. Due to their high conservation, assays based on the full-length N and F proteins may not distinguish HRSV from human metapneumovirus and other Mononegavirales viruses, and the full-length G protein would most likely produce false negative results due to its high divergence. MAIN CONCLUSIONS: We have identified specific regions in each of these three proteins that have higher potential to produce specific results, and their combined utilisation should be considered for immunoassay development.
[Mh] Termos MeSH primário: Variação Genética
Infecções por Vírus Respiratório Sincicial/virologia
Vírus Sincicial Respiratório Humano/genética
Proteínas Virais/genética
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Genótipo
Seres Humanos
Testes Imunológicos
Filogenia
Infecções por Vírus Respiratório Sincicial/diagnóstico
Vírus Sincicial Respiratório Humano/classificação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Viral Proteins)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE


  2 / 3415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28931055
[Au] Autor:Kelen D; Andorka C; Szabó M; Alafuzoff A; Kaila K; Summanen M
[Ad] Endereço:First Department of Pediatrics, Semmelweis University, Budapest, Hungary.
[Ti] Título:Serum copeptin and neuron specific enolase are markers of neonatal distress and long-term neurodevelopmental outcome.
[So] Source:PLoS One;12(9):e0184593, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The objective of this study was to evaluate the early changes in serial serum levels of copeptin and neuron-specific enolase (NSE) in neonates diagnosed with birth asphyxia, and to determine whether these biomarkers measured in the first 168 hours after birth are predictive of long-term neurodevelopmental outcome. Copeptin and NSE levels were measured from serum samples collected 6, 12, 24, 48, 72, and 168 hours after birth from 75 term neonates diagnosed with hypoxic-ischemic encephalopathy (HIE) and treated with therapeutic hypothermia for 72 hours. In addition, serum copeptin levels after birth were measured from 10 HIE diagnosed neonates, who were randomized to the normothermic arm of the TOBY cohort. All neonates underwent neurodevelopmental assessment using the Bayley Scales of Infant and Toddler Development-II at two years of age. Copeptin levels were highest at 6 hours after birth and steadily decreased, whereas the highest NSE levels were measured at 24 hours after birth. The biomarker levels correlated with blood-gas parameters (base excess, pH and lactate) at 6 and 12 hours after birth. Copeptin and NSE levels in the early postnatal period were significantly higher in neonates with poor outcome compared to those with favorable outcome at two years of age. Furthermore, in the TOBY cohort, copeptin levels were significantly lower in hypothermic compared to normothermic neonates. To conclude, copeptin and NSE measured in the early postnatal period are potential prognostic biomarkers of long-term neurodevelopmental outcome in term neonates diagnosed with HIE and treated with therapeutic hypothermia.
[Mh] Termos MeSH primário: Asfixia Neonatal/sangue
Biomarcadores/sangue
Glicopeptídeos/sangue
Hipotermia Induzida
Hipóxia-Isquemia Encefálica/sangue
Fosfopiruvato Hidratase/sangue
[Mh] Termos MeSH secundário: Asfixia Neonatal/terapia
Pré-Escolar
Feminino
Idade Gestacional
Seres Humanos
Hipóxia-Isquemia Encefálica/terapia
Testes Imunológicos
Lactente
Recém-Nascido
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers); 0 (Glycopeptides); 0 (copeptins); EC 4.2.1.11 (Phosphopyruvate Hydratase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170921
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0184593


  3 / 3415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28771597
[Au] Autor:Lucas JL; Tacheny EA; Ferris A; Galusha M; Srivastava AK; Ganguly A; Williams PM; Sachs MC; Thurin M; Tricoli JV; Ricker W; Gildersleeve JC
[Ad] Endereço:MRIGlobal, Gaithersburg, Maryland, United States of America.
[Ti] Título:Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy.
[So] Source:PLoS One;12(8):e0182739, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cancer therapies can provide substantially improved survival in some patients while other seemingly similar patients receive little or no benefit. Strategies to identify patients likely to respond well to a given therapy could significantly improve health care outcomes by maximizing clinical benefits while reducing toxicities and adverse effects. Using a glycan microarray assay, we recently reported that pretreatment serum levels of IgM specific to blood group A trisaccharide (BG-Atri) correlate positively with overall survival of cancer patients on PROSTVAC-VF therapy. The results suggested anti-BG-Atri IgM measured prior to treatment could serve as a biomarker for identifying patients likely to benefit from PROSTVAC-VF. For continued development and clinical application of serum IgM specific to BG-Atri as a predictive biomarker, a clinical assay was needed. In this study, we developed and validated a Luminex-based clinical assay for measuring serum IgM specific to BG-Atri. IgM levels were measured with the Luminex assay and compared to levels measured using the microarray for 126 healthy individuals and 77 prostate cancer patients. This assay provided reproducible and consistent results with low %CVs, and tolerance ranges were established for the assay. IgM levels measured using the Luminex assay were found to be highly correlated to the microarray results with R values of 0.93-0.95. This assay is a Laboratory Developed Test (LDT) and is suitable for evaluating thousands of serum samples in CLIA certified laboratories that have validated the assay. In addition, the study demonstrates that discoveries made using neoglycoprotein-based microarrays can be readily migrated to a clinical assay.
[Mh] Termos MeSH primário: Vacinas Anticâncer/uso terapêutico
Imunoglobulina M/sangue
Testes Imunológicos/métodos
Oligossacarídeos/imunologia
Neoplasias da Próstata/terapia
[Mh] Termos MeSH secundário: Biomarcadores/metabolismo
Seres Humanos
Masculino
Polissacarídeos/metabolismo
Neoplasias da Próstata/imunologia
Análise Serial de Proteínas
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Cancer Vaccines); 0 (Immunoglobulin M); 0 (Oligosaccharides); 0 (PROSTVAC); 0 (Polysaccharides); 0 (blood group A trisaccharide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170804
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182739


  4 / 3415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28674756
[Au] Autor:Meirow Y; Baniyash M
[Ad] Endereço:The Lautenberg Center for General and Tumor Immunology, Faculty of Medicine, Israel-Canada Medical Research Institute, The Hebrew University, POB 12272, 91120, Jerusalem, Israel.
[Ti] Título:Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases.
[So] Source:Cancer Immunol Immunother;66(8):1089-1101, 2017 Aug.
[Is] ISSN:1432-0851
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Chronic inflammation arising in a diverse range of non-cancerous and cancerous diseases, dysregulates immunity and exposes patients to a variety of complications. These include immunosuppression, tissue damage, cardiovascular diseases and more. In cancer, chronic inflammation and related immunosuppression can directly support tumor growth and dramatically reduce the efficacies of traditional treatments, as well as novel immune-based therapies, which require a functional immune system. Nowadays, none of the immune biomarkers, regularly used by clinicians can sense a developing chronic inflammation, thus complications can only be detected upon their appearance. This review focuses on the necessity for such immune status biomarkers, which could predict complications prior to their appearance. Herein we bring examples for the use of cellular and molecular biomarkers in diagnosis, prognosis and follow-up of patients suffering from various cancers, for prediction of response to immune-based anti-cancer therapy and for prediction of cardiovascular disease in type 2 diabetes patients. Monitoring such biomarkers is expected to have a major clinical impact in addition to unraveling of the entangled complexity underlying dysregulated immunity in chronic inflammation. Thus, newly discovered biomarkers and those that are under investigation are projected to open a new era towards combating the silent damage induced by chronic inflammation.
[Mh] Termos MeSH primário: Biomarcadores/metabolismo
Sistema Imunitário
Mediadores da Inflamação/metabolismo
Inflamação/imunologia
Neoplasias/imunologia
[Mh] Termos MeSH secundário: Animais
Detecção Precoce de Câncer
Seres Humanos
Tolerância Imunológica
Testes Imunológicos
Inflamação/diagnóstico
Neoplasias/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (Inflammation Mediators)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE
[do] DOI:10.1007/s00262-017-2035-6


  5 / 3415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28674112
[Au] Autor:Vyles D; Adams J; Chiu A; Simpson P; Nimmer M; Brousseau DC
[Ad] Endereço:Pediatric Emergency Medicine, dvyles@mcw.edu.
[Ti] Título:Allergy Testing in Children With Low-Risk Penicillin Allergy Symptoms.
[So] Source:Pediatrics;140(2), 2017 Aug.
[Is] ISSN:1098-4275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Penicillin allergy is commonly reported in the pediatric emergency department (ED). True penicillin allergy is rare, yet the diagnosis results from the denial of first-line antibiotics. We hypothesize that all children presenting to the pediatric ED with symptoms deemed to be low-risk for immunoglobulin E-mediated hypersensitivity will return negative results for true penicillin allergy. METHODS: Parents of children aged 4 to 18 years old presenting to the pediatric ED with a history of parent-reported penicillin allergy completed an allergy questionnaire. A prespecified 100 children categorized as low-risk on the basis of reported symptoms completed penicillin allergy testing by using a standard 3-tier testing process. The percent of children with negative allergy testing results was calculated with a 95% confidence interval. RESULTS: Five hundred ninety-seven parents completed the questionnaire describing their child's reported allergy symptoms. Three hundred two (51%) children had low-risk symptoms and were eligible for testing. Of those, 100 children were tested for penicillin allergy. The median (interquartile range) age at testing was 9 years (5-12). The median (interquartile range) age at allergy diagnosis was 1 year (9 months-3 years). Rash (97 [97%]) and itching (63 [63%]) were the most commonly reported allergy symptoms. Overall, 100 children (100%; 95% confidence interval 96.4%-100%) were found to have negative results for penicillin allergy and had their labeled penicillin allergy removed from their medical record. CONCLUSIONS: All children categorized as low-risk by our penicillin allergy questionnaire were found to have negative results for true penicillin allergy. The utilization of this questionnaire in the pediatric ED may facilitate increased use of first-line penicillin antibiotics.
[Mh] Termos MeSH primário: Erupção por Droga/diagnóstico
Hipersensibilidade a Drogas/diagnóstico
Serviço Hospitalar de Emergência
Testes Imunológicos/métodos
Testes Intradérmicos
Penicilinas/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Erupção por Droga/imunologia
Hipersensibilidade a Drogas/imunologia
Reações Falso-Positivas
Feminino
Seres Humanos
Imunoglobulina E/sangue
Masculino
Penicilinas/administração & dosagem
Penicilinas/imunologia
Inquéritos e Questionários
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Penicillins); 37341-29-0 (Immunoglobulin E)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE


  6 / 3415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28668856
[Au] Autor:Mariampillai AI; Cruz JPD; Suh J; Sivapiragasam A; Nevins K; Hindenburg AA
[Ad] Endereço:Department of Hematology and Oncology, NYU Winthrop Hospital, Mineola, NY, U.S.A.
[Ti] Título:Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries.
[So] Source:Anticancer Res;37(7):3649-3656, 2017 07.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cancer antigen CA72-4 is a tumor marker found to be elevated in a variety of human adenocarcinomas. Using the DRG TM-CA72-4, we quantified the elevation of CA72-4 compared to current United States Food And Drug Administration-approved tumor markers in various cancer types. MATERIALS AND METHODS: We conducted a prospective, single-center study enrolling 96 patients between March 2013 and August 2016 with different locally advanced, unresectable or metastatic cancer known to express CA72-4. Quantification of CA72-4 was performed according to the manufacturer's instructions using the DRG TM-CA72-4 enzyme-linked immunosorbent assay kit and the positivity rates were calculated. RESULTS: CA72-4 expression varied with tumoral site of origin, with the highest positivity rates found in pancreatic and ovarian malignancies. Correlation with clinical activity was also noted in some patients. CONCLUSION: CA72-4 may have a potential role as an adjunct to conventional biomarkers in disease monitoring of pancreatic, ovarian and colorectal carcinomas.
[Mh] Termos MeSH primário: Antígenos Glicosídicos Associados a Tumores/metabolismo
Neoplasias da Mama/metabolismo
Neoplasias Gastrointestinais/metabolismo
Neoplasias Pulmonares/metabolismo
Neoplasias Ovarianas/metabolismo
[Mh] Termos MeSH secundário: Idoso
Biomarcadores Tumorais/metabolismo
Antígeno CA-19-9/metabolismo
Feminino
Seres Humanos
Testes Imunológicos/métodos
Masculino
Meia-Idade
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Tumor-Associated, Carbohydrate); 0 (Biomarkers, Tumor); 0 (CA-19-9 Antigen); 0 (CA-72-4 antigen)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170703
[St] Status:MEDLINE


  7 / 3415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28654920
[Au] Autor:Saltabayeva U; Garib V; Morenko M; Rosenson R; Ispayeva Z; Gatauova M; Zulus L; Karaulov A; Gastager F; Valenta R
[Ad] Endereço:International Network of Universities for Molecular Allergololgy and Immunology, Vienna, Austria.
[Ti] Título:Greater Real-Life Diagnostic Efficacy of Allergen Molecule-Based Diagnosis for Prescription of Immunotherapy in an Area with Multiple Pollen Exposure.
[So] Source:Int Arch Allergy Immunol;173(2):93-98, 2017.
[Is] ISSN:1423-0097
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Allergen molecule-based diagnosis has been suggested to facilitate the identification of disease-causing allergen sources and the prescription of allergen-specific immunotherapy (AIT). The aim of the current study was to compare allergen molecule-based IgE serology with allergen extract-based skin testing for the identification of the disease-causing allergen sources. The study was conducted in an area where patients are exposed to pollen from multiple sources (trees, grasses, and weeds) at the same time to compare the diagnostic efficiency of the 2 forms of diagnosis. METHODS: Patients from Astana, Kazakhstan, who suffered from pollen-induced allergy (n = 95) were subjected to skin prick testing (SPT) with a local panel of tree pollen, grass pollen, and weed pollen allergen extracts and IgE antibodies specific for marker allergen molecules (nArt v 1, nArt v 3, rAmb a 1, rPhl p 1, rPhl p 5, rBet v 1) were measured by ImmunoCAP. Direct and indirect costs for diagnosis based on SPT and marker allergen-based IgE serology as well as direct costs for immunotherapy depending on SPT and serological test results were calculated. RESULTS: The costs for SPT-based diagnosis per patient were lower than the costs for allergen molecule-based IgE serology. However, allergen molecule-based serology was more precise in detecting the disease-causing allergen sources. A lower number of immunotherapy treatments (n = 119) was needed according to molecular diagnosis as compared to extract-based diagnosis (n = 275), which considerably reduced the total costs for diagnosis and for a 3-year treatment from EUR 1,112.30 to 521.77 per patient. CONCLUSIONS: The results from this real-life study show that SPT is less expensive than allergen molecule-based diagnostic testing, but molecular diagnosis allowed more precise prescription of immunotherapy which substantially reduced treatment costs and combined costs for diagnosis and treatment.
[Mh] Termos MeSH primário: Alérgenos/imunologia
Dessensibilização Imunológica
Testes Imunológicos/métodos
Proteínas de Plantas/imunologia
Pólen/imunologia
Rinite Alérgica/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Pré-Escolar
Custos e Análise de Custo
Feminino
Seres Humanos
Imunoglobulina E/sangue
Testes Imunológicos/economia
Masculino
Meia-Idade
Rinite Alérgica/economia
Rinite Alérgica/imunologia
Rinite Alérgica/terapia
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Allergens); 0 (Plant Proteins); 37341-29-0 (Immunoglobulin E)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.1159/000477442


  8 / 3415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28586426
[Au] Autor:Lum FM; Lin C; Susova OY; Teo TH; Fong SW; Mak TM; Lee LK; Chong CY; Lye DCB; Lin RTP; Merits A; Leo YS; Ng LFP
[Ad] Endereço:Singapore Immunology Network, Agency for Science, Technology and Research.
[Ti] Título:A Sensitive Method for Detecting Zika Virus Antigen in Patients' Whole-Blood Specimens as an Alternative Diagnostic Approach.
[So] Source:J Infect Dis;216(2):182-190, 2017 Jul 15.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Epidemics caused by the reemergence of Zika virus (ZIKV) warrant the need to develop new diagnostic measures to complement currently used detection methods. In this study, we explored the detection of ZIKV antigen in a defined leukocyte subset from patients' whole-blood specimens. Methods: Whole-blood samples were obtained at the acute and early convalescent phases from ZIKV-infected patients during the Singapore outbreak in August-September 2016. Presence of ZIKV antigen was determined by flow cytometry staining for intracellular ZIKV NS3, using a ZIKV-specific polyclonal antibody. The presence of ZIKV antigen was determined in CD45+CD14+ monocytes. Results: Data showed that ZIKV NS3 antigen could be detected in CD45+CD14+ monocytes. The levels of detection were further categorized into 3 groups: high (positivity among >40% of monocytes), moderate (positivity among 10%-40%), and low (positivity among <10%). While a majority of patients showed a decrease in the amount of ZIKV antigen detected at later time points, some patients displayed higher levels as the disease progressed. Conclusions: Our data highlights an alternative approach in using flow cytometry as a sensitive method for detecting ZIKV antigen in whole blood. Importantly, it further confirms the role of CD14+ monocytes as an important cellular target for ZIKV infection during the viremic phase.
[Mh] Termos MeSH primário: Antígenos Virais/sangue
Monócitos/imunologia
RNA Viral/sangue
Infecção pelo Zika virus/sangue
Infecção pelo Zika virus/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Reações Cruzadas
Epidemias
Feminino
Seres Humanos
Testes Imunológicos
Masculino
Meia-Idade
Monócitos/virologia
Singapura
Carga Viral
Adulto Jovem
Zika virus
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Viral); 0 (RNA, Viral)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170607
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix276


  9 / 3415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28554544
[Au] Autor:Joseph J; Kent N; Bowen A; Hart J; Sheel M; Wardrop R; Abbs S; Bazely S; Rybak M
[Ad] Endereço:PathWest Laboratory Medicine, QE2 Medical Centre Redevelopment, Australia. Electronic address: john.joseph@health.wa.gov.au.
[Ti] Título:Immuno-nephelometric determination of group streptococcal anti-streptolysin O titres (ASOT) from dried blood spots: Method for validating a new assay.
[So] Source:J Immunol Methods;448:59-65, 2017 Sep.
[Is] ISSN:1872-7905
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:This study was designed to determine the sensitivity and reproducibility of recovering anti-streptolysin O titres (ASOT) from dried blood spot (DBS) samples, a methodologic subcomponent of the penicillin pharmacokinetic studies in children receiving secondary prophylaxis with intramuscular benzathine penicillin for acute rheumatic fever.
[Mh] Termos MeSH primário: Antiestreptolisina/sangue
Teste em Amostras de Sangue Seco
Testes Imunológicos/métodos
Febre Reumática/diagnóstico
Estreptolisinas/imunologia
[Mh] Termos MeSH secundário: Antibacterianos/administração & dosagem
Antibacterianos/farmacocinética
Proteínas de Bactérias/imunologia
Biomarcadores/sangue
Calibragem
Desenho de Equipamento
Estudos de Viabilidade
Seres Humanos
Testes Imunológicos/instrumentação
Testes Imunológicos/normas
Injeções Intramusculares
Nefelometria e Turbidimetria
Penicilina G Benzatina/administração & dosagem
Penicilina G Benzatina/farmacocinética
Valor Preditivo dos Testes
Padrões de Referência
Reprodutibilidade dos Testes
Febre Reumática/sangue
Febre Reumática/tratamento farmacológico
Febre Reumática/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Biomarkers); 0 (Streptolysins); 0 (streptolysin O); 9006-92-2 (Antistreptolysin); RIT82F58GK (Penicillin G Benzathine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170531
[St] Status:MEDLINE


  10 / 3415 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28541299
[Au] Autor:Pisetsky DS
[Ad] Endereço:Medical Research Service, Durham Veterans Administration Medical Center, Box 151G, 508 Fulton Street, Durham, North Carolina 27705, USA; and at the Division of Rheumatology and Immunology, Duke University Medical Center, DUMC 3544, Durham, North Carolina 27710, USA.
[Ti] Título:Antinuclear antibody testing - misunderstood or misbegotten?
[So] Source:Nat Rev Rheumatol;13(8):495-502, 2017 Aug.
[Is] ISSN:1759-4804
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Antinuclear antibodies (ANAs) are a diverse group of autoantibodies that recognize nuclear macromolecules and their complexes. ANAs represent key biomarkers in the evaluation of rheumatic diseases, most prominently systemic lupus erythematosus (SLE), and ANA testing is commonly performed in the clinical setting. In addition, ANA testing is now used to assess eligibility for participation in clinical trials of new therapeutic agents for SLE. ANAs can be assayed by various techniques, with the fluorescent ANA assay often viewed as the gold standard. Whereas a positive ANA test represents a classification criterion for SLE, up to 20-30% of the healthy population, depending on the assay used, is positive for an ANA, complicating the use of this test for diagnosis or the detection of preclinical autoimmunity. Furthermore, ANAs might be expressed in SLE less commonly than often thought. This Perspectives article discusses important questions about the use of ANA testing in both the clinical and research settings.
[Mh] Termos MeSH primário: Anticorpos Antinucleares/metabolismo
Lúpus Eritematoso Sistêmico/diagnóstico
[Mh] Termos MeSH secundário: Biomarcadores/metabolismo
Seres Humanos
Testes Imunológicos
Lúpus Eritematoso Sistêmico/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Antinuclear); 0 (Biomarkers)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170823
[Lr] Data última revisão:
170823
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE
[do] DOI:10.1038/nrrheum.2017.74



página 1 de 342 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde